Condition P13B

Parkinson disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

People with Parkinson disease.

2 randomized trials; 0 fitted analyses across 7 outcomes.

All outcomes

Each outcome is analyzed per time window and estimand, with doses kept apart (each dose) and pooled (each medicine). Analyses with too few connected trials are shown as descriptive.

Motor function (Parkinson disease)primary

O101

Time window	Estimand	Treatments	Trials	Nodes	Analysis
weeks 36 to 78 (target week 52)	Not stated by the trials	Each dose separately	1	2	Descriptive only
weeks 36 to 78 (target week 52)	Not stated by the trials	Doses of a drug pooled	1	2	Descriptive only

Serious adverse events

O25

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only

Discontinuation due to adverse events

O26

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Nausea

O27A

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Vomiting

O27B

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Diarrhea

O27C

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only

Constipation

O27D

Time window	Estimand	Treatments	Trials	Nodes	Analysis
longest follow-up	Recorded harms	Each dose separately	1	2	Descriptive only
longest follow-up	Recorded harms	Doses of a drug pooled	1	2	Descriptive only